Cargando…

EGFR-TKI在非小细胞肺癌中耐药机制的研究进展

Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NS...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015174/
https://www.ncbi.nlm.nih.gov/pubmed/24113007
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.07
_version_ 1783334350915371008
collection PubMed
description Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NSCLC. The standard treatment to advanced NSCLC is platinum-based combined chemotherapy. However, chemotherapy drugs usually have limited effects on improving the survival of the patients. Then exploring new therapies is extremely urgent to us. Now, molecular targeted therapy has been the most promising research area for the treatment of NSCLC with researches going deep into pathogenesis and biological behavior of lung cancer. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have achieved a great success in the treatment of advanced NSCLC. Their representatives are erlotinib and gefitinib. The two drugs have been widely used to treat advanced NSCLCs worldwide, especially for the patients with EGFR activating mutations. However, after a period of treatment (median time is 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to TKIs: primary and acquired resistances. The research about resistance mechanism of NSCLC to EGFR-TKIs is a hot one because of their excellent effects on improving overall and progression-free survival. The aim of this article was to summarize the development of the resistance mechanisms.
format Online
Article
Text
id pubmed-6015174
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60151742018-07-06 EGFR-TKI在非小细胞肺癌中耐药机制的研究进展 Zhongguo Fei Ai Za Zhi Tki耐药专题 Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NSCLC. The standard treatment to advanced NSCLC is platinum-based combined chemotherapy. However, chemotherapy drugs usually have limited effects on improving the survival of the patients. Then exploring new therapies is extremely urgent to us. Now, molecular targeted therapy has been the most promising research area for the treatment of NSCLC with researches going deep into pathogenesis and biological behavior of lung cancer. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have achieved a great success in the treatment of advanced NSCLC. Their representatives are erlotinib and gefitinib. The two drugs have been widely used to treat advanced NSCLCs worldwide, especially for the patients with EGFR activating mutations. However, after a period of treatment (median time is 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to TKIs: primary and acquired resistances. The research about resistance mechanism of NSCLC to EGFR-TKIs is a hot one because of their excellent effects on improving overall and progression-free survival. The aim of this article was to summarize the development of the resistance mechanisms. 中国肺癌杂志编辑部 2013-10-20 /pmc/articles/PMC6015174/ /pubmed/24113007 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.07 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle Tki耐药专题
EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title_full EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title_fullStr EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title_full_unstemmed EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title_short EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
title_sort egfr-tki在非小细胞肺癌中耐药机制的研究进展
topic Tki耐药专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015174/
https://www.ncbi.nlm.nih.gov/pubmed/24113007
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.07
work_keys_str_mv AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn
AT egfrtkizàifēixiǎoxìbāofèiáizhōngnàiyàojīzhìdeyánjiūjìnzhǎn